These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 38745575)

  • 21. Summaries of Safety Labeling Changes Approved By FDA-Boxed Warnings Highlights April-June 2015.
    Am J Health Syst Pharm; 2015 Sep; 72(17):1430. PubMed ID: 26294231
    [No Abstract]   [Full Text] [Related]  

  • 22. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, October-December 2018.
    Am J Health Syst Pharm; 2019 Mar; 76(7):412. PubMed ID: 31361824
    [No Abstract]   [Full Text] [Related]  

  • 23. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, October-December 2020.
    Am J Health Syst Pharm; 2021 Mar; 78(6):460-461. PubMed ID: 33693575
    [No Abstract]   [Full Text] [Related]  

  • 24. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, October through December 2019.
    Am J Health Syst Pharm; 2020 Apr; 77(8):603. PubMed ID: 32236461
    [No Abstract]   [Full Text] [Related]  

  • 25. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, October-December 2018.
    Am J Health Syst Pharm; 2019 Mar; 76(7):e6-e7. PubMed ID: 31361826
    [No Abstract]   [Full Text] [Related]  

  • 26. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, October-December 2020.
    Am J Health Syst Pharm; 2021 Mar; 78(6):e3-e5. PubMed ID: 33693576
    [No Abstract]   [Full Text] [Related]  

  • 27. Summaries of Safety Labeling Changes Approved By FDA- Boxed Warnings Highlights October-December 2017.
    Hosp Pharm; 2018 Jun; 53(3):134-135. PubMed ID: 30147130
    [No Abstract]   [Full Text] [Related]  

  • 28. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, October-December 2017.
    Office of Health and Constituent Affairs, U.S. Food and Drug Administration
    Am J Health Syst Pharm; 2018 Mar; 75(5):e113-e114. PubMed ID: 29472516
    [No Abstract]   [Full Text] [Related]  

  • 29. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, October-December 2017.
    Office of Health and Constituent Affairs, U.S. Food and Drug Administration
    Am J Health Syst Pharm; 2018 Mar; 75(5):259. PubMed ID: 29472507
    [No Abstract]   [Full Text] [Related]  

  • 30. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, October-December 2016.
    Am J Health Syst Pharm; 2017 Mar; 74(5):277-278. PubMed ID: 28213489
    [No Abstract]   [Full Text] [Related]  

  • 31. Summaries of safety labeling changes approved by FDA-boxed warnings highlights October-December 2021.
    Am J Health Syst Pharm; 2022 Mar; 79(7):e93-e95. PubMed ID: 35217869
    [No Abstract]   [Full Text] [Related]  

  • 32. Summaries of safety labeling changes approved by FDA-boxed warnings highlights, October-December 2021.
    Am J Health Syst Pharm; 2022 Mar; 79(7):525-526. PubMed ID: 35224616
    [No Abstract]   [Full Text] [Related]  

  • 33. Summaries of safety labeling changes approved by FDA-boxed warnings highlights, January-March 2024.
    Am J Health Syst Pharm; 2024 Jun; 81(13):e330-e334. PubMed ID: 38801728
    [No Abstract]   [Full Text] [Related]  

  • 34. Summaries of safety labeling changes approved by FDA-boxed warnings highlights, April-June 2024.
    Am J Health Syst Pharm; 2024 Aug; 81(17):e455-e456. PubMed ID: 39058929
    [No Abstract]   [Full Text] [Related]  

  • 35. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, January-March 2017.
    Office of Health and Constituent Affairs, U.S. Food and Drug Administration
    Am J Health Syst Pharm; 2017 Jun; 74(11):e292-e294. PubMed ID: 28546306
    [No Abstract]   [Full Text] [Related]  

  • 36. Summaries of Safety Labeling Changes Approved By FDA-Boxed Warnings Highlights July-September 2015.
    Am J Health Syst Pharm; 2015 Dec; 72(23):e60-8. PubMed ID: 26581940
    [No Abstract]   [Full Text] [Related]  

  • 37. "Black box" 101: How the Food and Drug Administration evaluates, communicates, and manages drug benefit/risk.
    Murphy S; Roberts R
    J Allergy Clin Immunol; 2006 Jan; 117(1):34-9. PubMed ID: 16387581
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Summaries of Safety Labeling Changes Approved By FDA--Boxed Warnings Highlights July--September 2015.
    Am J Health Syst Pharm; 2015 Dec; 72(23):2008. PubMed ID: 26581924
    [No Abstract]   [Full Text] [Related]  

  • 39. Provisional CDC guidelines for the use and safety monitoring of bedaquiline fumarate (Sirturo) for the treatment of multidrug-resistant tuberculosis.
    Centers for Disease Control and Prevention
    MMWR Recomm Rep; 2013 Oct; 62(RR-09):1-12. PubMed ID: 24157696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Summaries of safety labeling changes approved by FDA-Boxed warnings highlights, January-March 2019.
    Am J Health Syst Pharm; 2019 Jun; 76(13):e8-e9. PubMed ID: 31361888
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.